Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-08
2008-11-25
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S309000, C514S367000, C514S394000, C514S395000, C514S414000, C514S416000, C514S417000, C544S373000, C546S141000, C548S178000, C548S306100, C548S306400, C548S307100, C548S307400, C548S309400, C548S309700, C548S466000, C548S467000, C548S470000, C548S471000, C548S472000, C548S473000, C548S476000, C548S477000, C548S480000, C548S481000
Reexamination Certificate
active
07456183
ABSTRACT:
Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
REFERENCES:
patent: 3177218 (1965-04-01), Brown
patent: 4128643 (1978-12-01), Merkel et al.
patent: 4287341 (1981-09-01), Hess et al.
patent: 4496571 (1985-01-01), Yellin et al.
patent: 4732916 (1988-03-01), Satoh et al.
patent: 4748165 (1988-05-01), Jones et al.
patent: 4824835 (1989-04-01), Mertens et al.
patent: 4874864 (1989-10-01), Schnur et al.
patent: 4948891 (1990-08-01), Schnur et al.
patent: 4948901 (1990-08-01), Schnur et al.
patent: 5086057 (1992-02-01), Sasagawa et al.
patent: 5124328 (1992-06-01), Fisher et al.
patent: 5352704 (1994-10-01), Okuyama et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5637439 (1997-06-01), Kaneko et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5866579 (1999-02-01), Wong et al.
patent: 5885985 (1999-03-01), MacDonald et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 5962530 (1999-10-01), Engel et al.
patent: 6020349 (2000-02-01), Ankersen et al.
patent: 6030985 (2000-02-01), Gentile et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6060589 (2000-05-01), Stark et al.
patent: 6127343 (2000-10-01), Ankersen et al.
patent: 6225331 (2001-05-01), Cupps et al.
patent: 6297233 (2001-10-01), Stein et al.
patent: 6391878 (2002-05-01), Cupps et al.
patent: 6638927 (2003-10-01), Renhowe et al.
patent: 6716840 (2004-04-01), Chu et al.
patent: 6960582 (2005-11-01), Boyce
patent: 2004/0024211 (2004-02-01), Boyce et al.
patent: 2005/0038027 (2005-02-01), Boyce et al.
patent: 0 354 553 (1990-02-01), None
patent: 0 343 894 (1992-06-01), None
patent: WO 96/04270 (1996-02-01), None
patent: WO 96/24580 (1996-08-01), None
patent: WO 97/19911 (1997-06-01), None
patent: WO 97/41119 (1997-11-01), None
patent: WO 98/07420 (1998-02-01), None
patent: WO 98/11095 (1998-03-01), None
patent: WO 98/23596 (1998-06-01), None
patent: WO 98/46572 (1998-10-01), None
patent: WO 99/26942 (1999-06-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/17191 (2000-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 01/55148 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/83485 (2001-11-01), None
patent: WO 02/062776 (2002-08-01), None
patent: WO 03/099818 (2003-12-01), None
Wolff (Ed.),Burger's Medicinal Chemistry and Drug Discovery, 5thEdition, vol. 1: Principles and Practice, 1995, pp. 975-977, John Wiley & Sons, Inc.
Banker et al. (Eds.),Modern Pharmaceutics, 3rdEdition, Revised and Expanded, 1996, pp. 451 and 596, Marcel Dekker, Inc.
West,Solid State Chemistry and its Applications, 1988, pp. 358 and 365, John Wiley & Sons, Inc.
Goodfellow et al., “The Melanocortin System and its Role in Obesity and Cachexia,”Current Topics in Medicinal Chemistry, 2003, pp. 855-883, vol. 3, No. 8, Bentham Science Publishers Ltd.
Fisher et al., “Melanocortin-4 receptor: A novel signaling pathwway involved in body weight regulation,”International Journal of Obesity, 1999, pp. 54-58, vol. 23, Suppl. 1, Stockton Press.
Runti et al., “Fusaric Acid Derivatives and Analogues as Possible Antihypertensive Drugs,”Il Farmaco—Ed. Sc., 1981, pp. 260-268, vol. 36, No. 4.
Alexander et al., “(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes,”J. Med. Chem., 1988, pp. 318-322, vol. 31, No. 2.
Bell et al., “Efficient synthesis of 1-heterocyclic-3-aminopyrrolidinones,”Tetrahedron Letters, 2000, pp. 1141-1145, vol. 41, Elsevier Science Ltd.
Bhattacharyya et al., “Selective Monoalkylation of Ammonia: A High Throughput Synthesis of Primary Amides,”Synlett, 1999, pp. 1781-1783, No. 11, Thieme Stuttgart, New York.
Brown et al., “Organoboranes for Synthesis. 7. An Improved General Synthesis of Primary Amines From Alkene via Hydroboration-Organoborane Chemistry,”Tetrahedron, 1987, pp. 4071-4078, vol. 43, No. 18, Pergamon Journals Ltd., Great Britain.
Carey et al.,Advanced Organic Chemistry, Part A: Structure and Mechanisms, 3rdEdition, 1990, Table of Contents Only, Plenum Press, New York and London.
Fong et al., “ART (Protein Product of Agouti-Related Transcript) as a Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Research Communications, 1997, pp. 629-631, vol. 237, No. 3, Article No. RC977200, Academic Press.
Furniss et al.,Vogel's Textbook of Practical Organic Chemistry, 5thEdition, 1989, Table of Contents Only, Longman Scientific & Technical and John Wiley & Sons, Inc., New York, USA.
Greene,Protective Groups in Organic Synthesis, 1981, Table of Contents Only, John Wiley & Sons, New York, USA.
Hadley et al., “The Proopiomelanocortin System,”Annals New York Academy of Sciences, 1999, pp. 1-21, vol. 885.
http://www.idealibrary.com/links.doi/10.1006/bbrc.1997, Fong et al., “ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Research Communications, Aug. 28, 1997, pp. 629-631, vol. 237, No. 3, ISSN:0006-291X, EISSN:1090-2104, Abstract Only.
http://www.sciencemag.org/...ar=2001&hits=10&sendit.x=36&sendit.y, Ollman et al., “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, Oct. 3, 1997, pp. 135-138, vol. 278.
Huszar et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell, Jan. 10, 1997, pp. 131-141, vol. 38, Cell Press.
Julia et al., “Amidines et guanidines apparentées á la congocidine,”Bulletin De La Société Chimique De France, 1968, pp. 376-382, No. 1.
Kiefer et al., “Mutations in the Carboxyl Terminus of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors,”Biochemistry, 1997, pp. 2084-2090, vol. 36, American Chemical Society.
LaRock,Comprehensive Organic Transformations, A Guide to Functional Group Preparations, 1989, Table of Contents Only, VCH Publishers, Inc., USA.
Lu et al., “Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor,”Nature, Oct. 27, 1994, pp. 799-802, vol. 371.
March,Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, 3rdEdition, 1985, Table of Contents Only, John Wiley & Sons.
Mickelson et al., “Asymmetric Synthesis of 2,6-Methylated Piperazines,”J. Org. Chem., 1995, pp. 4177-4183, vol. 60, No. 13, American Chemical Society.
Mountjoy et al., “The Cloning of a Family of Genes that Encode the Melanocortin Receptors,”Science, Aug. 28, 1992, pp. 1248-1251, vol. 257.
Nevy et al., “Transition State Imbalance in the Deprotonation of Substituted 2-Tetralones by Hydroxide Ion,”J. Am. Chem. Soc., 1997, pp. 12722-12726, vol. 119, No. 52, American Chemical Society.
Ollmann et al., “Antagonism of Central Melanocortin Receptors in Vitro
Boyce Rustum
Chang Bryan
Chu Daniel
Duhl David
Coleman Brenda L
Kathardekar Vinit
Meara Joseph P.
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Guanidino compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidino compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidino compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031288